Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. N0821: A phase II first-line study of a combination of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results